Log In
BCIQ
Print this Print this
 

XmAb14045

Also known as: CD3 x CD123

  Manage Alerts
Collapse Summary General Information
Company Xencor Inc.
DescriptionBispecific antibody against CD3 and IL-3 receptor alpha (CD123)
Molecular Target CD3 ; Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,550.0M

$150.0M

$2,400.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/28/2016

$2,550.0M

$150.0M

$2,400.0M

Get a free BioCentury trial today